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Background—Several observational studies have reported that HIV-1 acquisition seems to be 
higher in women who use depot medroxyprogesterone acetate (DMPA) than in those who do not 
use hormonal contraception. We aimed to assess whether two injectable progestin-only 
contraceptives, DMPA and norethisterone enanthate (NET-EN), confer different risks of HIV-1 
acquisition.
Methods—We included data from South African women who used injectable contraception 
while participating in the VOICE study, a multisite, randomised, placebo-controlled trial that 
investigated the safety and efficacy of three formulations of tenofovir for prevention of HIV-1 
infection in women between Sept 9, 2009, and Aug 13, 2012. Women were assessed monthly for 
contraceptive use and incident infection. We estimated the difference in incident HIV-1 infection 
between DMPA and NET-EN users by Cox proportional hazards regression analyses in this 
prospective cohort. The VOICE trial is registered with ClinicalTrials.gov, NCT00705679.
Findings—3141 South African women using injectable contraception were included in the 
present analysis: 1788 (56·9%) solely used DMPA, 1097 (34·9%) solely used NET-EN, and 256 
(8·2%) used both injectable types at different times during follow-up. During 2733·7 person-years 
of follow-up, 207 incident HIV-1 infections occurred (incidence 7·57 per 100 person-years, 95% 
CI 6·61–8·68). Risk of HIV-1 acquisition was higher among DMPA users (incidence 8·62 per 100 
person-years, 95% CI 7·35–10·11) than among NET-EN users (5·67 per 100 person-years, 4·35–
7·38; hazard ratio 1·53, 95% CI 1·12–2·08; p=0·007). This association persisted when adjusted for 
potential confounding variables (adjusted hazard ratio [aHR] 1·41, 95% CI 1·06–1·89; p=0·02). 
Among women seropositive for herpes simplex virus type 2 (HSV-2) at enrolment, the aHR was 
2·02 (95% CI 1·26–3·24) compared with 1·09 (0·78–1·52) for HSV-2-seronegative women 
(pinteraction=0·07).
Interpretation—Although moderate associations in observational analyses should be interpreted 
with caution, these findings suggest that NET-EN might be an alternative injectable drug with a 
lower HIV risk than DMPA in high HIV-1 incidence settings where NET-EN is available.
Funding—National Institutes of Health, Mary Meyer Scholars Fund, and the Ruth Freeman 
Memorial Fund.
Introduction
Although benefits of contraception generally outweigh potential risks to women’s health, 1,2 
results of observational studies that assessed the effect of hormonal contraception on HIV-1 
acquisition are mixed.3 In light of findings that suggest increased HIV risk in women who 
use the injectable progestin depot medroxyprogesterone acetate (DMPA), WHO 
recommended “women using progestogen-only injectable contraception should be strongly 
advised to also always use condoms, male or female, and other HIV preventive measures”.4 
WHO also recommended that injectable contraceptive alternatives to DMPA be investigated 
for associations with HIV acquisition in women.5 Updated WHO guidance acknowledged 
these mixed findings and the need for further research.6 This uncertainty is especially 
problematic in sub-Saharan Africa, where HIV incidence among young women is high and 
use of injectable contraception is common.7–9
Noguchi et al. Page 2













In eastern and southern Africa, injectable methods are the most popular contraceptives, 
accounting for over 40% of use.10 South African women are increasingly using 
injectables:9,11,12 about half of women using contraception use injectable progestin 
methods, although estimates reach nearly 90% in some areas.11 The two commonly used 
methods are DMPA 150 mg, a progesterone derivative used every 3 months,13 and 
norethisterone enanthate (NET-EN) 200 mg, a first-generation synthetic progestin used 
every 2 months.14,15 Although more South African women use DMPA than use NET-EN,11 
both are highly effective (97%, typical use); are available in the public sector, where most 
women obtain contraception;9 have the same medical eligibility criteria;16 and are treated 
similarly in policy guidance.16 However, their pharmacokinetic profiles differ and 
amenorrhoea and delayed return to ovulation seem to be more common in DMPA users than 
in NET-EN users.17,18 Findings from in-vitro studies that showed different progestins affect 
immune cells differently suggest risk of HIV-1 acquisition could differ between these two 
methods.19,20 In a recent systematic review21 and an individual participant data meta-
analysis,22 hazard ratios (HRs) for HIV acquisition were higher for DMPA (1·40, 95% CI 
1·16–1·69;21 and 1·50, 1·24–1·83)22 than for NET-EN (1·10, 0·88–1·37;21 and 1·24, 0·84–
1·82)22 when either method was compared with no hormonal contraception. So far, no 
published studies assessing separate progestin types have implicated NET-EN in HIV 
acquisition, although a recent systematic review reported an unpublished reanalysis of study 
data suggesting increased risk of HIV-1 infection associated with NET-EN, compared with 
use of no hormonal contraception.3 However, NET-EN-specific data are limited.
Most analyses of hormonal contraception and HIV-1 acquisition have used comparator 
groups of women who do not use hormonal contraception.3 However, a limitation of this 
approach is that it compares groups with potentially different HIV-related risk behaviours, 
including un protected intercourse and coital frequency.23,24 These differential risks of 
exposure could confound associations between contraceptive type and HIV acquisition. 
However, restricting analysis to one delivery system (ie, injection) might address potential 
behavioural confounding by contraceptive type and allow more direct comparison between 
two hormonal contraception types of interest. A proposed randomised controlled trial of 
contraceptive methods would have no comparison group of women not taking contraception, 
similar to our approach.25 Herein, we sought to quantify the difference in HIV-1 acquisition 
in DMPA and NET-EN users.
Methods
Study design and participants
We analysed prospective data from the VOICE trial (MTN-003), a randomised, placebo-
controlled trial that investigated the safety and efficacy of three formulations of tenofovir for 
prevention of HIV-1 infection in women (NCT00705679). Women were enrolled from 
South Africa (Durban, Johannesburg, and Klerksdorp), Uganda, and Zimbabwe from Sept 9, 
2009, to June 7, 2011, and were followed up until Aug 13, 2012.26 Women who were HIV 
uninfected, sexually active, not pregnant, without curable genitourinary infection, and 
willing to use effective contraception (hormonal method, intrauterine device, or sterilisation) 
were eligible for inclusion. Women who were breastfeeding, or who had abnormal renal, 
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haematological, or hepatic function were excluded. Adherence to VOICE study drugs was 
low, and no regimen significantly reduced HIV-1 acquisition compared with placebo.26 In 
the present study, we restricted analysis to participants in South Africa, where both DMPA 
and NET-EN are used. We postulated there would be no difference in acquisition between 
DMPA and NET-EN users.
Participants provided written informed consent before enrolment into the VOICE trial. 
Institutional review boards in South Africa, Uganda, the USA, and Zimbabwe approved the 
VOICE trial, with additional approval for this analysis provided by Johns Hopkins 
Bloomberg School of Public Health Institutional Review Board.
Procedures
Women attended monthly visits for study product management, completion of standardised 
questionnaires, documentation of contraceptive use, pregnancy testing, and HIV testing. 
Sensitive questions (eg, on sexual practices) were also asked via audio computer-assisted 
self-interview (ACASI). All participants were provided condoms and standard risk reduction 
counselling. Testing for HIV was done according to protocol-defined algorithms. Screening 
for chlamydia, gonorrhoea, and trichomonas infection was done at baseline, annually, and 
when clinically indicated, with treatment provided on site. Herpes simplex virus type 2 
(HSV-2) status at baseline and study end was determined via FOCUS EIA (Focus 
Technologies, Cypress, CA, USA).
Statistical analysis
The VOICE protocol prespecified an analysis of contraceptive use and HIV-1 acquisition; 
the primary comparison of DMPA versus NET-EN use was designed Nov 9, 2012, after 
completion of the VOICE trial, but before data unmasking and primary data analysis. On the 
basis of anticipated number of HIV endpoints in the VOICE trial, we estimated 80–90% 
power to detect a 50% difference in hazard of acquisition between DMPA and NET-EN 
users. To compare baseline characteristics between DMPA and NET-EN users, we grouped 
participants according to initial exposure after enrolment. We estimated exposure using 
injection dates, which were recorded in clinic charts for on-site injections and transcribed 
from contraception cards for off-site injections. Exposure lengths per injection (17 weeks for 
DMPA and 10 weeks for NET-EN) were based on WHO guidelines for duration of 
contraceptive coverage.27 We did not assume continued administration of injections during 
missed visits. Separate binary variables were created for DMPA and NET-EN. Person-time 
was set to unexposed when modelled exposure lengths ended; unexposed person-time was 
excluded. We identified and adjusted for periods when combined oral contraceptive pill 
(binary variable) and injectable exposure overlapped (eg, to treat breakthrough vaginal 
bleeding). Date of HIV-1 infection was estimated by calculation of the midpoint between 
last negative test and first confirmed positive test.
We used a Cox proportional hazards model with time-varying exposure to compare HIV 
acquisition between DMPA and NET-EN users. Follow-up time was from enrolment until 
estimated date of HIV-1 infection, pregnancy, loss to follow-up, or last negative HIV test. 
The time origin for the model was the date of first contraceptive injection resulting in 
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exposure during follow-up. We included person-time for both injectable types, including 
those participants who switched types during follow-up. We adjusted for baseline age, 
marriage or cohabitation, education, and HSV-2 serostatus; time-varying factors included 
combined oral contraceptive pill use, condom use at last sex (ACASI), and whether primary 
partners had other partners (ACASI). Because of overall low adherence to VOICE study 
products, we did not adjust by trial arm. Potential confounding variables were selected on 
the basis of clinical relevance. We calculated a multilevel, site-stratified estimate in the 
adjusted model because of variable HIV-1 incidence by site. We used clustering of 
variance–covariance estimation methods to calculate SEs, allowing for intragroup 
correlation at site level. Use of a marginal structural model to address time-dependent 
confounding was considered; however, intermittent combined oral contraceptive pill use and 
pregnancy were deemed potential violations of the positivity assumption requisite for 
marginal structural model validity.28
We did three prespecified subgroup analyses: women who reported at baseline not using 
condoms for vaginal sex in the past week (ACASI), women aged less than 25 years, and 
women with HSV-2 versus those without HSV-2 at baseline. We used the likelihood ratio 
test to assess the interaction between injectable type and HSV-2 serostatus in the adjusted 
model. We tested model sensitivity to censoring at pregnancy detection via an additional 
analysis omitting all pregnant person-time, but with allowance for return to assessment after 
pregnancy outcomes (subgroup analysis, not prespecified). We also assessed results in those 
with baseline chlamydia, gonorrhoea, or trichomonas infection, as potentially objective 
markers for recent unprotected sex (subgroup analysis, not prespecified). Lastly, as a 
strategy to investigate potential provider bias in prescriptive patterns, we repeated the 
model, restricting to, and then omitting, participants who used both injectable methods at 
different times during follow-up (subgroup analysis, not prespecified). All analyses were 
done with Stata version 13.1. All statistical tests were two-sided with a probability of type I 
error of 0·05.
The VOICE trial is registered with ClinicalTrials.gov, NCT00705679.
Role of the funding source
The National Institutes of Health participated in study design and oversight, data 
interpretation, and writing of the report, and provided an independent data and safety 
monitoring board to review the VOICE trial every 6 months; they had no role in data 
collection or data analysis. Mary Meyer Scholars Fund and the Ruth Freeman Memorial 
Fund had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the data in the study. Protocol chairs 
(ZMC and JMM) and sponsor representatives (JMP and DHW) had final responsibility for 
the decision to submit for publication.
Results
Of 5029 participants in the VOICE trial, 3141 South African injectable contraception users 
were included in the present analysis. Of the 1888 excluded participants, 33 were missing 
data for injectable contraceptive type and 22 were identified by plasma HIV-1 RNA PCR as 
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infected at enrolment (figure). Of 3141 participants included in the secondary analyses, 1788 
(56·9%) solely used DMPA, 1097 (34·9%) solely used NET-EN, and 256 (8·2%) used both 
injectable types at different times during follow-up (figure). Because most participants did 
not switch injectable type, the first injectable was DMPA in 1927 women (61·3%) and NET-
EN in 1214 (38·7%). Most women were young and unmarried (table 1). Women whose first 
injectable was DMPA were older (p<0·0001), more likely to be married or cohabitating 
(p=0·0004), more likely to be parous (p<0·0001), and less likely to report multiple partners 
(p=0·0001) or circumcised partners (p<0·0001). The median number of sex acts in the past 
week was similar, but the distribution was weighted toward fewer among NET-EN users 
(p=0·004). Recent anal sex was more commonly reported by those whose first injectable was 
NET-EN (p=0·04). Baseline seropositivity for HSV-2 was higher for those whose first 
method was DMPA (p<0·0001).
Overall median follow-up for women was 13·3 months (IQR 9·4–16·5) and was similar 
between groups (p=0·3). Women whose first injectable was DMPA more frequently 
continued participation until originally scheduled termination of study participation (1786 of 
1925 [92·8%] vs 1085 of 1214 [89·4%]; p=0·001). Reasons for 268 women with early 
termination were death (three), refusal of further participation (127), relocation (61), loss to 
follow-up (41), investigator decision (one), and other reasons (35).
629 (20·0%) of 3141 participants had three or more consecutive missed visits during follow-
up. 268 users of DMPA (13·9%) used combined oral contraceptive pills (alone or 
concurrently with injectable) during follow-up compared with 333 NET-EN users (27·4%; 
p<0·0001). Among those who started injectable use with DMPA, 32 (1·7%) became 
pregnant during follow-up compared with 38 (3·1%) NET-EN users (p=0·007); overall 
pregnancy incidence (0·5% for both methods) did not differ during DMPA and NET-EN 
exposure (p=0·9). Condom use was more frequently reported at quarterly follow-up visits 
for DMPA than for NET-EN users (p=0·01; table 2).
Overall, 207 new HIV-1 infections occurred over 2733·7 person-years of follow-up, 
resulting in an incidence of 7·57 per 100 person-years (95% CI 6·61–8·68; table 3): 152 
during 1763·0 person-years of DMPA use (8·62 per 100 person-years, 7·35–10·11) and 55 
during 970·8 person-years of NET-EN use (5·67 per 100 person-years, 4·35–7·38). Overall 
risk of HIV-1 infection was higher in DMPA users than in NET-EN users (HR 1·53, 95% CI 
1·12–2·08; p=0·007). This association persisted in a site-stratified, multivariable model 
adjusted for baseline and time-varying factors (adjusted HR [aHR] 1·41, 95% CI 1·06–1·89; 
p=0·02). Additional adjustment for number of sexual partners and receptive anal sex did not 
substantially alter results. Use of a categorical variable for HSV-2 (remained HSV-2 
seronegative, acquired HSV-2, or HSV-2-seropositive at baseline) also resulted in a similar 
estimate (aHR 1·42, 95% CI 1·06–1·90; p=0·02). HIV-1 incidence varied by site (2·18–10·40 
per 100 person-years). We did not find evidence of a statistical interaction by study site 
(pinteraction=0·6).
Among women who were seronegative for HSV-2 at baseline, no significant difference in 
risk of HIV was noted between DMPA and NET-EN users (p=0·6; table 3). However, 
among women who were seropositive for HSV-2 at baseline, we noted a higher risk of 
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incident HIV infection in DMPA compared with NET-EN users (aHR 2·01, 95% CI 1·12–
3·63 vs 1·09, 0·78–1·52; pinteraction=0·07). Repeating the primary comparison in the whole 
cohort, with the addition of injection exposures and person-time after pregnancy outcomes, 
did not substantially alter the results. Results were similar if analysis was restricted to those 
diagnosed with trichomonas, chlamydia, or gonorrhoea infection at baseline. Lastly, when 
we restricted analysis to women who used both DMPA and NET-EN (at different times) 
during follow-up, DMPA was associated with higher risk of HIV than was NET-EN (aHR 
4·76, 95% CI 2·15–10·52; p=0·0001).
Discussion
In this large prospective study of South African women who use injectable progestin-only 
contraception, those using DMPA had about a 50% increase in incident HIV-1 infection 
compared with those using NET-EN; increased risk persisted after controlling for important 
demographic and behavioural factors and in several sensitivity analyses. Present WHO 
recommendations suggest progestin-only injectable methods have the potential to increase 
risk of HIV acquisition;6 our results suggest risk might differ across different progestin-only 
injectable types.
As VOICE required all participants to be using contraception at enrolment, our analyses 
cannot address whether DMPA or NET-EN increases risk of HIV-1 acquisition in women 
compared with no use of hormonal contraception. We are also unable to assess potential 
HIV infection risk associated with combination injectable methods (oestrogen plus progestin 
in a single formulation) because those methods were not used by any VOICE participants. 
However, these results might offer clinically relevant information for the millions of women 
at risk for HIV who want to use progestin-only injectable contraception, particularly those 
unable to negotiate condom use or who live where non-hormonal alternatives are scarce. 
The more common comparison of DMPA versus no hormonal contraception is appropriate 
when estimating the effect of DMPA on HIV acquisition,23 but comparisons between 
methods have greater utility for women who want to avoid pregnancy and for contraceptive 
providers. Moreover, a comparison between two different injectable methods is less likely to 
be confounded by behavioural differences (eg, condom use, coital frequency, or partner 
selection) than are comparisons between hormonal and non-hormonal methods of 
contraception. In view of the high incidence of HIV-1 in this cohort, our findings support 
WHO recommendations6 that condoms are available to couples in which the woman is using 
injectable progestogen contraception. However, condom use is frequently outside women’s 
control, and this persistent inequity contributes to demand for injectable contraceptives, 
which can be used independent of partners’ knowledge or consent. In this cohort, women 
not using condoms at baseline had overall lower HIV risk than the whole cohort, which 
might be related to both risk perception and partner choice. Scale-up is needed for 
alternatives to injectable methods such as implants and non-hormonal methods (eg, the 
copper intrauterine device), although the effect of implants on HIV risk has been estimated 
in only a few analyses.29 Development of multipurpose technologies for prevention of both 
HIV infection and undesired pregnancy is also needed.
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Among women who were seropositive for HSV-2 at baseline, DMPA was associated with a 
two times increased risk of HIV acquisition compared with NET-EN, whereas this 
association was not noted among women who were seronegative for HSV-2 at baseline. Our 
findings differ from those of previous studies that compared DMPA or pooled hormonal 
contraception versus no hormonal contraception, which reported either an increased risk of 
HIV acquisition among HSV-2 seronegative women30 or no suggestion of modification of 
effect by HSV-2 status.31–33 Thus, data are insufficient to inform clinical guidance 
specifically for women with known or suspected HSV-2 infection.
Because analysis of hormonal contraception and HIV-1 acquisition was planned in the 
VOICE trial, we prospectively implemented robust data collection and site monitoring 
strategies for this cohort, one of the largest so far with regard to person-time and HIV 
infection. Measurements of contraceptive exposure, sexual behaviour, pregnancy, and HIV 
status were frequent for a study of this type. Contraception was offered on site, and injection 
types and dates were directly reported or identified from family planning cards, rather than 
self-report. Frequent measurement of contraceptive use allowed precise characterisation of 
exposures relative to HIV outcome, reducing but not eliminating potential exposure 
misclassification. The design of the VOICE trial also permitted simultaneous investigation 
of genital tract infection, and frequency of prevalent or incident gonorrhoea or chlamydia 
did not differ between DMPA and NET-EN users, as might be expected if the reported 
increase in HIV acquisition were related solely to differences in behaviour (eg, condom 
use).34
Although our results seem to be consistent with those of in-vitro analyses that suggest 
proinflammatory effects of DMPA compared with NET-EN19,20 and a recent meta-analysis 
that suggests higher risk of HIV in users of DMPA than in users of NET-EN,22 ultimately 
our findings do not identify potential mechanisms for differences in HIV-1 acquisition. The 
main limitation of this study is possible bias—a substantial risk in all observational analyses, 
which have limited capacity to detect slight associations reliably.35 In this cohort, in which 
partners’ HIV serostatus was not assessed, true exposure levels to infection are unknown 
and potentially differed between injectable groups. The inclusion of only clinical trial 
participants limits the generalisability of our results. Social desirability might have affected 
measurement of self-reported covariates, such as condom use. Although we postulated that 
DMPA and NET-EN users were more similar to each other with regards to HIV risk than to 
women not using hormonal contraception, we noted differences between women in the two 
contraceptive groups that suggest we cannot completely circumvent analytical challenges 
related to possible confounding and group comparability. First, DMPA users were more 
likely to continue follow-up until scheduled termination, which potentially affected 
estimates for comparative risk of HIV acquisition. Some factors, such as partner’s 
circumcision status, uncertainty about a partner’s other partners or HIV status, and 
participant’s HSV-2 serostatus, might suggest higher HIV risk for DMPA than for NET-EN 
users. However, other differences between groups (eg, age, and knowing a primary partner 
had other partners or HIV) potentially suggest higher HIV risk in NET-EN users, although 
we did not identify this in our results. Thus, demographic and behavioural differences 
between DMPA and NET-EN users do not suggest a consistent direction for bias. Some 
differences between DMPA and NET-EN users, particularly age, have been reported 
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previously and are probably a result of misperceptions that NET-EN is more appropriate for 
younger women who want future fertility,36 which suggests that socio-demographic 
differences between injectable users persist despite contemporary messaging to discourage 
age-based prescribing.37,38 Lastly, pharma cokinetic profiles differ between progestin types 
and among women, and physiological effects are known to outlast detectable drug in some 
women;39 thus, our exposure definitions might not demarcate the most relevant exposure 
periods.
HIV-1 infection does not exist in isolation from other substantial health risks for women in 
sub-Saharan Africa, including maternal mortality. In South Africa, modern contraception 
has averted an estimated 58% of potential maternal deaths.1 Benefits of contraception also 
include reduced deaths of newborn babies, improved child health, and increased household 
income.40 Thus, concerns about possible increased HIV risk with DMPA use must be 
weighed against the beneficial effects of contraception on a broad range of outcomes. 
Despite findings that might implicate DMPA in HIV acquisition, evidence remains mixed, 
and withdrawal of any common effective contraceptive could increase maternal mortality 
rates.41 The present data suggest that NET-EN might be an alternative injectable drug with a 
lower HIV risk than DMPA, and policy makers, clinician scientists, and community 
stakeholders should continue to assess emerging evidence to establish whether women who 
prefer an injectable, in consultation with providers, should consider switching from DMPA 
to NET-EN in high HIV incidence settings where NET-EN is available.
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Evidence before this study
We searched PubMed for articles published before March 18, 2015, using the terms 
“hormonal contraception”, “HIV/acquisition”, “injectable”, “progestin”, “progestogen”, 
“depot medroxyprogesterone acetate”, “DMPA”, “norethisterone enanthate”, and “NET-
EN”, in different combinations. We also reviewed systematic reviews and meta-analyses 
on this topic. Recent findings from a systematic review and an individual participant data 
meta-analysis showed higher hazard ratios for depot medroxyprogesterone acetate 
(DMPA) than norethisterone enanthate (NET-EN) when either method was compared 
with use of no hormonal contraception. No published studies that disaggregated type of 
progestin have implicated NET-EN in HIV-1 acquisition, although a recent systematic 
review reported an unpublished reanalysis of study data that suggested an increased risk 
of infection associated with NET-EN, compared with no hormonal contraception. When 
assessed in the same study, some unpublished point estimates for HIV-1 risk were larger 
for NET-EN than for DMPA.
Added value of this study
Most analyses of hormonal contraception and HIV-1 acquisition have used comparator 
groups of women who do not use hormonal contraception. However, a limitation of this 
approach is comparison between groups with potentially different HIV risk behaviours, 
including unprotected intercourse and coital frequency. Restricting analysis to one 
delivery system (ie, injection) might address potential behavioural confounding by 
contraceptive type and allow more direct comparison between hormonal contraception 
types of interest. Our results might offer clinically relevant information for women at risk 
of HIV who want to use progestin-only injectable contraception, particularly those unable 
to negotiate condom use or who live where non-hormonal alternatives are scarce.
Implications of all the available evidence
Concerns about possible increased HIV-1 risk with DMPA use must be weighed 
carefully against the beneficial effects of contraception on public health. Despite 
observational findings that seem to implicate DMPA in HIV acquisition, evidence 
remains mixed, and withdrawal of any common effective contraceptive could increase 
maternal mortality ratios. A broad range of stakeholders should continue to assess 
emerging evidence to establish whether women, in consultation with providers, should 
consider switching from DMPA to NET-EN in high HIV incidence settings where NET-
EN is available.
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DMPA=depot medroxyprogesterone acetate. NET-EN=norethisterone enanthate.
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Table 1
Demographics and baseline characteristics of women by first injectable method type
Whole cohort (n=3141) DMPA first (n=1927) NET-EN first (n=1214)
p value DMPA first 
vs NET-EN first
Demographics
Age (years)* 23 (21–27) 24 (21–27) 23 (20–26) <0·0001
Married or cohabitating 603/3141 (19·2%) 408/1927 (21·2%) 195/1214 (16·1%) 0·0004
Parous 2632/3141 (83·8%) 1786/1927 (92·7%) 846/1214 (69·7%) <0·0001
Any secondary education 3017/3137 (96·2%) 1839/1924 (95·6%) 1178/1213 (97·1%) 0·03
Formal employment 299/3138 (9·5%) 178/1925 (9·2%) 121/1213 (10·0%) 0·5
Home ownership 2585/3139 (82·4%) 1585/1926 (82·3%) 1000/1213 (82·4%) 0·9
Sexual behaviours
>1 sexual partner 118/3101 (3·8%) 53/1912 (2·8%) 65/1189 (5·5%) 0·0001
Number of sex acts in the past week* 2 (1–3) 2 (1–3) 2 (0–3) 0·004
Condom used at last sex 2132/2858 (74·6%) 1299/1748 (74·3%) 833/1110 (75·0%) 0·7
Anal sex in the past 3 months 628/3090 (20·3%) 364/1900 (19·2%) 264/1190 (22·2%) 0·04
Sex for money in the past year 155/3112 (5·0%) 93/1917 (4·9%) 62/1195 (5·2%) 0·7
Primary partner
Any secondary education 2891/3119 (92·7%) 1764/1917 (92·0%) 1127/1202 (93·8%) 0·07
Has other partners 0·03
 Yes 285/3038 (9·4%) 163/1889 (8·6%) 122/1149 (10·6%) ··
 No 801/3038 (26·4%) 479/1889 (25·4%) 322/1149 (28·0%) ··
 Don’t know 1952/3038 (64·3%) 1247/1889 (66·0%) 705/1149 (61·4%) ··
Circumcised <0·0001
 Yes 1001/3120 (32·1%) 556/1918 (29·0%) 445/1202 (37·0%) ··
 No 1727/3120 (55·4% 1123/1918 (58·6%) 604/1202 (50·2%) ··
 Don’t know 392/3120 (12·6%) 239/1918 (12·5%) 153/1202 (12·7%) ··
HIV infected 0·0006
 Yes 104/3036 (3·4%) 61/1887 (3·2%) 43/1149 (3·7%) ··
 No 2039/3036 (67·2%) 1224/1887 (64·9%) 815/1149 (70·9%) ··
 Don’t know 893/3036 (29·4%) 602/1887 (31·9%) 291/1149 (25·3%) ··
Genital tract infections
Bacterial vaginosis† 1246/3137 (39·7%) 762/1925 (39·6%) 484/1212 (39·9%) 0·9
Trichomoniasis 174/3141 (5·5%) 114/1927 (5·9%) 60/1214 (4·9%) 0·2
Chlamydia 468/3141 (14·9%) 289/1927 (15·0%) 179/1214 (14·7%) 0·8
Gonorrhoea 110/3141 (3·5%) 67/1927 (3·5%) 43/1214 (3·5%) 0·9
Herpes simplex virus type 2 1459/3130 (46·6%) 985/1926 (51·1%) 474/1204 (39·4%) <0·0001
Data are median (IQR) or n/N (%). Comparisons between participants were calculated with the Wilcoxon rank-sum test for continuous variables 
and Pearson’s χ2 test for categorical variables. Some percentages do not add up to 100 because of rounding.
*
Reported as median (IQR) because of right-skewed distributions.













Noguchi et al. Page 15
†
Nugent score ≥7 for Gram-stained vaginal smear.
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Table 2
Sexual behaviour during quarterly follow-up intervals for analysis of HIV-1 acquisition with DMPA and 
NET-EN use (n=3141 seronegative women)
DMPA NET-EN p value*
Condom use at last vaginal sex act 4934/5999 (82·3%) 2527/3233 (78·2%) 0·002
More than one sex partner 148/6571 (2·3%) 93/3521 (2·6%) 0·3
Change in primary partner 618/7136 (8·7%) 404/3767 (10·7%) 0·06
Anal sex in the past 3 months 1133/7498 (15·1%) 545/3936 (13·9%) 0·4
Sex for money in the past year 349/7466 (4·7%) 222/3892 (5·7%) 0·4
Data are number of reports/number of quarterly visits with each characteristic (assessed by ACASI) during study follow-up (%), unless otherwise 
specified.
*
Comparisons among contraceptive exposure groups are adjusted for correlation by multiple measures from the same woman with generalised 
estimating equations.
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